Talphera Inc. (TLPH) - Total Liabilities
Based on the latest financial reports, Talphera Inc. (TLPH) has total liabilities worth $12.40 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check TLPH asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Talphera Inc. - Total Liabilities Trend (2008–2025)
This chart illustrates how Talphera Inc.'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see TLPH asset base.
Talphera Inc. Competitors by Total Liabilities
The table below lists competitors of Talphera Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
EasyJet PLC
LSE:EZJ
|
UK | GBX9.08 Billion |
|
Bonus Biogroup
TA:BONS
|
Israel | ILA21.11 Million |
|
Sunsuria Bhd
KLSE:3743
|
Malaysia | RM1.27 Billion |
|
Mink Therapeutics Inc
NASDAQ:INKT
|
USA | $23.64 Million |
|
Jade Gas Holdings Ltd
AU:JGH
|
Australia | AU$12.28 Million |
|
Isbir Sentetik Dokuma Sanayi AS
IS:ISSEN
|
Turkey | TL5.09 Billion |
|
HSS Engineers Bhd
KLSE:0185
|
Malaysia | RM178.00 Million |
|
Noble Development Public Company Limited
BK:NOBLE
|
Thailand | ฿16.07 Billion |
Liability Composition Analysis (2008–2025)
This chart breaks down Talphera Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Talphera Inc. (TLPH) net asset quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.29 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.86 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Talphera Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Talphera Inc. (2008–2025)
The table below shows the annual total liabilities of Talphera Inc. from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $12.68 Million | +23.93% |
| 2024-12-31 | $10.24 Million | +62.72% |
| 2023-12-31 | $6.29 Million | -75.50% |
| 2022-12-31 | $25.67 Million | -77.44% |
| 2021-12-31 | $113.79 Million | -6.77% |
| 2020-12-31 | $122.05 Million | -8.08% |
| 2019-12-31 | $132.77 Million | +14.18% |
| 2018-12-31 | $116.28 Million | +3.76% |
| 2017-12-31 | $112.06 Million | +6.39% |
| 2016-12-31 | $105.33 Million | +11.26% |
| 2015-12-31 | $94.67 Million | +138.11% |
| 2014-12-31 | $39.76 Million | +7.83% |
| 2013-12-31 | $36.87 Million | +20.21% |
| 2012-12-31 | $30.67 Million | +31.27% |
| 2011-12-31 | $23.37 Million | -67.87% |
| 2010-12-31 | $72.72 Million | +7.76% |
| 2009-12-31 | $67.48 Million | +20.48% |
| 2008-12-31 | $56.01 Million | -- |
About Talphera Inc.
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat… Read more